Description
A prodrug form of lysipressin; a partial agonist of the vasopressin V1A receptor (Ki = 0.85 µM); an agonist of vasopressin V1B and V2 receptors (Kis = 1.11 and 1.58 µM, respectively); increases MAP and decreases mortality in a rat model of uncontrolled hemorrhagic shock at 15 µg/kg; improves vascular reactivity and increases survival time in a rat model of cecal ligation and puncture-induced septic shock and a rabbit model of LPS-induced septic shock at 2.6 µg/kg per hour in combination with norepinephrine; increases MAP in a rat model of liver cirrhosis
Formal name: N-(glycylglycylglycyl)-8-L-lysine-vasopressin
Synonyms: Glycylpressin|Remestyp
Molecular weight: 1,227.40
CAS: 14636-12-5
Purity: ≥95%
Formulation: A crystalline solid
Product Type|Biochemicals|Receptor Pharmacology|Agonists||Research Area|Cardiovascular System|Cardiovascular Diseases|Hypertension||Research Area|Immunology & Inflammation|Innate Immunity|Sepsis/Shock